Clinical trials: Immune Deficiency
Human Immunodeficiency Virus (HIV) Infection
Safety, Reactogenicity and Immunogenicity of HB-502 and HB-501 Versus Placebo in People With HIV on Suppressive ART
This is a study of HB-502 and HB-501 alternating 2-vector therapy in people living with human immunodeficiency virus (HIV) who are taking antiretroviral treatment (ART).
- Trial name
- NCT06430905
- Testing
- HB-502 and HB-501 alternating 2-vector therapy Dose Level 1, HB-502 and HB-501 alternating 2-vector therapy Dose Level 2
- Where
- 5 sites in United States
- Volunteers
- 30 people
- Sponsor
- Hookipa Biotech GmbH
Human Immunodeficiency Virus Infections
Safety, PK and PD Study of ABX464 in Untreated HIV Patients
ABX464 is a first in class that showed efficacy as an anti-HIV therapy. The present study is intended to assess the safety, the tolerability, and pharmacokinetic parameters and to evaluate the effect on viral load of repeated…
- Trial name
- NCT02452242
- Testing
- ABX464
- Where
- 4 sites in Mauritius, Thailand
- Volunteers
- 70 people
- Sponsor
- Abivax S.A.
Ataxia Telangiectasia, Genetic Syndrome
Extension Treatment Using EryDex System in Patients With AT Who Participated in the ATTeST-IEDAT-02-2015 Study
Primary Objective To monitor and evaluate the long-term safety and tolerability of EDS-EP in AT patients. Secondary Objective To evaluate the long-term effect of EDS-EP on health-related Quality of Life (QoL; EQ-5D-5L scale).
- Trial name
- OLE-IEDAT (NCT03563053)
- Testing
- EryDex System
- Where
- 17 sites in United States, Australia and 9 more
- Volunteers
- 104 people
- Sponsor
- Quince Therapeutics S.p.A.
COVID-19, HIV Infections
Immunogenicity and Safety of an Inactivated COVID-19 Vaccine in People With HIV Infected
Evaluation of immunogenicity and safety of the subjects infected with HIV to receive the schedule of two doses inactivated COVID-19 vaccine with the interval of 21 days .
- Trial name
- NCT05075070
- Testing
- Inactivated COVID-19 vaccine
- Where
- China
- Volunteers
- 400 people
- Sponsor
- China National Biotec Group Company Limited
Cytomegalovirus Infections, HIV Infections
A Study of Lobucavir in Patients With AIDS
The purpose of this study is to see if lobucavir is a safe and effective treatment for cytomegalovirus in patients with AIDS.
- Trial name
- NCT00002352
- Testing
- Lobucavir
- Where
- 3 sites in United States
- Volunteers
- 30 people
- Sponsor
- Bristol-Myers Squibb
HIV Infections
Phase I Study of Alferon N Injection in Persons With Asymptomatic Human Immunodeficiency Virus (HIV) Infection
To determine the safety and tolerance of subcutaneous injections of natural interferon alpha (IFN) in asymptomatic HIV-positive persons and record its effects on the HIV virus in these individuals.
- Trial name
- NCT00002078
- Testing
- Interferon alfa-n3
- Where
- 2 sites in United States
- Sponsor
- Purdue Frederick
HIV Infection
Safety and Efficacy Study of Switching From Epzicom to Truvada
This protocol describes a prospective, randomized, open-label, multicenter study to evaluate the safety and efficacy of switching from fixed dose abacavir (ABC)/lamivudine (3TC) to fixed dose emtricitabine (FTC)/tenofovir…
- Trial name
- SWIFT (NCT00724711)
- Testing
- emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF), abacavir (ABC)/lamivudine (3TC)
- Where
- 80 sites in United States, Canada and 1 more
- Volunteers
- 312 people
- Sponsor
- Gilead Sciences
Lymphoma, Non-Hodgkin, HIV Infections
Gene Therapy in HIV-Positive Patients With Non-Hodgkin's Lymphoma
The purpose of this study is to see if it is safe and effective to use gene therapy to treat non-Hodgkin's lymphoma (NHL) in HIV-positive patients. Stem cell transplantation is a procedure used to treat NHL.
- Trial name
- NCT00002221
- Testing
- Peripheral blood stem cells
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Ribozyome
Asymptomatic HIV Infection
Evaluation of the Safety, Efficacy, and Pharmacokinetics of Intravenous Deferiprone in HIV-Positive Subjects
This study will evaluate the safety, tolerability, antiretroviral activity, pharmacokinetics, and pharmacodynamics of an intravenous formulation of deferiprone in HIV-infected subjects.
- Trial name
- NCT02456558
- Testing
- Intravenous deferiprone
- Where
- 2 sites in South Africa
- Volunteers
- 30 people
- Sponsor
- ApoPharma
HIV Infections
Combination of Efavirenz and Truvada - COMET Study
To characterize the risks (safety and tolerability), effectiveness (continued viral load suppression and CD4 changes), and benefits (safety, tolerability, adherence, general satisfaction with the treatment regimen and QoL), of…
- Trial name
- NCT00224458
- Testing
- Truvada, efavirenz
- Volunteers
- 400 people
- Sponsor
- Gilead Sciences
Human Immunodeficiency Virus (HIV), HIV Pre-Exposure Prophylaxis
A Drug-Drug Interaction Study of MK 8527 With a Combined Oral Contraceptive (LNG/EE)
This study is designed to assess the effect of a single dose of MK-8527 on the single-dose pharmacokinetics (PK) and the safety and tolerability of levonorgestrel/ethinyl estradiol (LNG/EE) in healthy adult postmenopausal or…
- Trial name
- NCT06783192
- Testing
- MK-8527, LNG/EE
- Where
- United States
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
HIV-Infections
TMC125HIV1083 - Swallowability of Uncoated 200 mg Etravirine Tablets in HIV-1 Infected Patients
This trial is designed to assess the swallowability of uncoated and film-coated 200 mg etravirine tablets in HIV-1 infected patients.
- Trial name
- NCT01090648
- Testing
- etravirine
- Volunteers
- 49 people
- Sponsor
- Tibotec Pharmaceuticals, Ireland
Hereditary Angioedema (HAE), Hereditary Angioedema - Type 1
Phase 3 Extension Study of ADX-324 in Participants With Hereditary Angioedema (HAE)
Study ADX-324-302 is an extension study for participants who complete the Phase 3 ADX-324-301 trial. The extension study will provide information about the safety and efficacy of additional dosing of ADX-324 in participants with…
- Conditions
- Hereditary Angioedema (HAE), Hereditary Angioedema - Type 1, Hereditary Angioedema - Type 2, HAE
- Trial name
- NCT07428499
- Testing
- ADX-324 Dose Level 1, ADX-324 Dose Level 2
- Where
- 48 sites in United States, Argentina and 17 more
- Volunteers
- 90 people
- Sponsor
- ADARx Pharmaceuticals, Inc.
HIV Infections
Feasibility Study of a Vaginal Ring for Delivery of TMC120 (Dapivirine)
The purpose of this trial was to evaluate the safety and feasibility of using a vaginal ring to deliver the candidate microbicide TMC120 (dapivirine).
- Trial name
- NCT00700284
- Testing
- TMC120 (dapivirine) vaginal ring
- Where
- Belgium
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- International Partnership for Microbicides, Inc.
HIV Infections
A Study of an Oral Entry Inhibitor, SP01A, in Treatment-Experienced HIV-Infected Patients
One measurement of an HIV infected person's risk of progressing to AIDS is the number of viral particles of HIV in their blood (called a "viral load").
- Trial name
- NCT00113412
- Testing
- SP01A
- Where
- 7 sites in United States
- Volunteers
- 32 people
- Sponsor
- Samaritan Pharmaceuticals, Inc
Candidiasis, Chronic Mucocutaneous
CAMB/MAT2203 in Patients With Mucocutaneous Candidiasis
This is an open-label, dose-titration trial to study the efficacy, safety, and pharmacokinetics of oral cochleate amphotericin B (CAMB) in the treatment of mucocutaneous candidiasis infections in patients who are refractory or…
- Trial name
- CAMB (NCT02629419)
- Testing
- Amphotericin B
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Matinas BioPharma Nanotechnologies, Inc.
Anemia, HIV
A Study to Assess the Effectiveness of PROCRIT (Epoetin Alfa) Dosing Every 2 Weeks Versus Once a Week in Anemic HIV-infected Patients
The purpose of this study is to determine if PROCRIT® (a glycoprotein that stimulates red blood cell production) initiated at once every 2 weeks dosing is as effective as PROCRIT® initiated at once a week dosing, in increasing…
- Trial name
- NCT00246298
- Testing
- epoetin alfa
- Volunteers
- 31 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
HIV-infection
Study in Healthy Volunteers to Investigate the Safety, Tolerability and Pharmacokinetics of VM-1500
A randomized single dose, drug-drug interaction study in healthy volunteers for VM - 1500 given alone or in combination with Raltegravir or Darunavir in a 3 arm approach.
- Trial name
- NCT02489487
- Testing
- VM-1500, Darunavir, Ritonavir
- Where
- Thailand
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Viriom
Infection, Human Immunodeficiency Virus
Bioavailability Study of a Dolutegravir Dispersible Tablet and Effect of Different Types of Water on the Dispersible Tablet in Healthy Volunteers
Dolutegravir (DTG) is an HIV-1 integrase inhibitor approved in the United States, Canada, Australia and EU. A dispersible tablet has been developed for pediatric use as an alternative to the granule formulation, already in…
- Trial name
- NCT02185300
- Testing
- Dolutegravir Pediatric Granules, Dolutegravir Dispersible Tablet
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- ViiV Healthcare
HIV Infections
A Study to Find the Best Dosing Schedule for Delavirdine, Zidovudine, and Indinavir in HIV-Positive Patients
The purpose of this study is to see whether it is better to take delavirdine (DLV) plus indinavir (IDV) plus zidovudine (ZDV) twice a day or three times a day.
- Trial name
- NCT00002236
- Testing
- Indinavir sulfate, Delavirdine mesylate, Zidovudine
- Where
- 6 sites in United States
- Volunteers
- 32 people
- Sponsor
- Pharmacia and Upjohn